At Shire, we believe that eye health is an important component of overall health and well-being at every stage of life.
We bring our unique and specialized disease expertise to treating conditions of the eye. Our commitment to providing potential therapies in ophthalmology stems from the same focus that drives our discovery, development, and delivery of new treatments for each of our therapeutic areas: patient need.
At the moment, we are particularly committed to dry eye disease, and have compounds at various stages of development for glaucoma, and infectious conjunctivitis. But we have a strong desire to expand in the near term, from conditions that affect the front of the eye to those that affect the back of the eye. We are engaged across the entire ophthalmology community and listen to patients and professionals as we evaluate more opportunities to advance progress in eye health.
Dry Eye Disease
Dry eye disease is a prevalent, multifactorial, and often chronic disease of the ocular surface.1,2 It is one of the most common conditions with which patients present to eye care professionals.1 Estimates suggest that between 5% and 50% of adults across the world could be suffering with dry eye disease, either with our without symptoms.2,3 Dry eye disease is most commonly associated with eye dryness and overall eye discomfort, and may also include a feeling of stinging or burning in the eyes, or episodes of fluctuating blurry vision.1
- Linert, J. et al. (2016). “Long-term Natural History of Dry Eye Disease from the Patient’s Perspective”. Ophthalmology. 123(2):425-433.
- Gayton, J. (2009). “Etiology, prevalence, and treatment of dry eye disease”. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2720680/. [Last accessed August 2017].
- Nelson, J. Daniel et al. (2017). “TFOS DEWS II Introduction”. The Ocular Surface. 15(3):269-275.